

PRESS RELEASE – FOR IMMEDIATE DIFFUSION

## **IntegraGen Announces Collaborative Agreement with Pfizer to Evaluate IntegraGen’s Proprietary Hepatocellular Carcinoma Molecular Signature**

EVRY, France, April 3, 2014, - **IntegraGen**, a leading player in the development and marketing of molecular diagnostic testing in oncology and autism, announced today that it has entered into an agreement with Pfizer Inc. that provides Pfizer access to evaluate the company’s proprietary molecular signature for hepatocellular carcinoma. The 56-gene molecular signature covered by the agreement is intended to predict the clinical prognosis of patients with hepatocellular carcinoma and subcategorize patients into six separate classifications based on the molecular characteristics of their liver tumors.

*“We are pleased to have our molecular signature evaluated by one of the world’s leading pharmaceutical companies,”* said Dr. Bernard Courtieu, IntegraGen’s Chief Executive Officer. *“The use of our molecular signature may help to identify specific patient populations who would benefit from Pfizer’s experimental compounds, if approved by regulatory authorities. We are also extremely appreciative of the research conducted by Professor Jessica Zucman-Rossi, which led to the development of this molecular signature with the continued support of the French League Against Cancer Program ‘Cartes d’Identité des Tumeurs®’ (CIT).”*

Terms of the agreement were not disclosed.

### **ABOUT INTEGRAGEN**

Founded in 2000, IntegraGen (ALINT.PA) is a biotechnology company focused on the development and commercialization of molecular diagnostic tests in the fields of autism and oncology. IntegraGen’s mission is to translate molecular research into clinical practice through the identification of novel genetic biomarkers and the subsequent development of molecular diagnostic tests which allow clinicians to better manage the clinical care of their patients. IntegraGen is also a leader in delivering expert genomic service solutions to academic researchers and life sciences companies as a result of its scientific knowledge and technological expertise related to cutting edge genomic platforms and bioinformatics.

For more information on IntegraGen visit [www.integragen.com](http://www.integragen.com)

**ABOUT THE FRENCH LEAGUE AGAINST CANCER**

The French League Against Cancer is a non-profit, non-governmental organization that is an independent voluntary funder of research against cancer. With nearly 700,000 members and 13,000 volunteers, the League is a grassroots movement organized into a federation of 103 local committees. Together, they fight in three complementary directions: search for cure, prevent to protect, support for help. Today, the League is making the fight against cancer a societal issue bringing together the largest possible number of health actors but also economic, social or political actors in all territories. Breaking taboos and fears, the League contributes to change the image of cancer and those who are affected. The French League Against Cancer finances and manages a national program of cancer genomics, called CIT "Cartes d'Identité des Tumeurs®" (Tumors Identity Cards). This program (<http://cit.ligue-cancer.net>) aims at characterizing multiple tumor types on a pangenomic scale to progress toward personalized medicine.

For more information visit [www.ligue-cancer.net](http://www.ligue-cancer.net) or follow us at [www.facebook.com/laliguecontrecancer](https://www.facebook.com/laliguecontrecancer) or at [twitter.com/laliguecancer](https://twitter.com/laliguecancer)

**Contact**

**INTEGRAGEN**

Bernard COURTIEU

CEO

Laurence RIOT LAMOTTE

CFO

[contact@integragen.com](mailto:contact@integragen.com)

Tel.: +33 (0)1 60 91 09 00

**NEWCAP.**

**Investor and Media relations**

Emmanuel HUYNH

Louis-Victor DELOUVRIER

[integragen@newcap.fr](mailto:integragen@newcap.fr)

Tel.: +33 (0)1 44 71 94 94

**FRENCH LEAGUE AGAINST CANCER**

Elodie Audonnet,

[Elodie.audonnet@ligue-cancer.net](mailto:Elodie.audonnet@ligue-cancer.net)

Tel: +33 (0) 1 53 55 25 31